DE60313344D1 - Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen - Google Patents

Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Info

Publication number
DE60313344D1
DE60313344D1 DE60313344T DE60313344T DE60313344D1 DE 60313344 D1 DE60313344 D1 DE 60313344D1 DE 60313344 T DE60313344 T DE 60313344T DE 60313344 T DE60313344 T DE 60313344T DE 60313344 D1 DE60313344 D1 DE 60313344D1
Authority
DE
Germany
Prior art keywords
pyridylmethyl
medicament
myelodysplastic syndromes
treatment
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313344T
Other languages
English (en)
Other versions
DE60313344T2 (de
Inventor
Margaret Han Dugan
Alan List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
University of Arizona
Original Assignee
Novartis AG
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, University of Arizona filed Critical Novartis AG
Application granted granted Critical
Publication of DE60313344D1 publication Critical patent/DE60313344D1/de
Publication of DE60313344T2 publication Critical patent/DE60313344T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60313344T 2002-09-24 2003-09-23 Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen Expired - Lifetime DE60313344T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
US413176P 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
DE60313344D1 true DE60313344D1 (de) 2007-05-31
DE60313344T2 DE60313344T2 (de) 2008-01-03

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313344T Expired - Lifetime DE60313344T2 (de) 2002-09-24 2003-09-23 Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Country Status (22)

Country Link
US (1) US20060128716A1 (de)
EP (1) EP1545534B1 (de)
JP (1) JP2006502195A (de)
KR (1) KR20050074450A (de)
CN (1) CN100372535C (de)
AT (1) ATE359789T1 (de)
AU (1) AU2003299065B2 (de)
BR (1) BR0314647A (de)
CA (1) CA2499738A1 (de)
CR (1) CR7754A (de)
DE (1) DE60313344T2 (de)
EC (1) ECSP055700A (de)
ES (1) ES2285251T3 (de)
HR (1) HRP20050281A2 (de)
MX (1) MXPA05003161A (de)
NO (1) NO20051936L (de)
PL (1) PL374696A1 (de)
PT (1) PT1545534E (de)
RS (1) RS20050228A (de)
RU (1) RU2353364C2 (de)
WO (1) WO2004028542A1 (de)
ZA (1) ZA200502212B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751932B2 (en) * 1997-10-15 2002-08-29 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1165085B1 (de) * 1999-03-30 2006-06-14 Novartis AG Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DE60030770T2 (de) * 1999-12-06 2007-09-06 Rhode Island Hospital Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen

Also Published As

Publication number Publication date
US20060128716A1 (en) 2006-06-15
RU2353364C2 (ru) 2009-04-27
CR7754A (es) 2005-12-02
CN1684684A (zh) 2005-10-19
ZA200502212B (en) 2006-02-22
PT1545534E (pt) 2007-06-22
BR0314647A (pt) 2005-08-02
MXPA05003161A (es) 2005-09-12
AU2003299065B2 (en) 2006-10-26
RU2005112711A (ru) 2006-02-27
EP1545534A1 (de) 2005-06-29
DE60313344T2 (de) 2008-01-03
ATE359789T1 (de) 2007-05-15
NO20051936L (no) 2005-06-23
JP2006502195A (ja) 2006-01-19
ECSP055700A (es) 2005-08-11
AU2003299065A1 (en) 2004-04-19
KR20050074450A (ko) 2005-07-18
HRP20050281A2 (en) 2006-07-31
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
RS20050228A (en) 2007-08-03
EP1545534B1 (de) 2007-04-18
CA2499738A1 (en) 2004-04-08
WO2004028542A1 (en) 2004-04-08
PL374696A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE511835T1 (de) Biophosphonate zur behandlung von endometriose
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
ATE517881T1 (de) 1-phenyl-2-heteroaryl-substituierte benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln zur behandlung von immunologischen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN